{'fraction_non_alphanumeric': 0.02218430034129693, 'fraction_numerical': 0.0, 'mean_word_length': 6.623376623376624, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Vancomycin serum trough concentration vs. clinical outcome in patients with gram‐positive infection: a retrospective analysis

Vancomycin is still the first‐line treatment for resistant gram‐positive infections, particularly for methicillin‐resistant Staphylococcus aureus (MRSA) infections. The vancomycin treatment guideline is based on the association between vancomycin trough concentration and clinical outcome. We here present a retrospective analysis of whether the trough level of vancomycin is associated with clinical outcome in Chinese patients with gram‐positive infections.